A
NYSEAgilent Technologies Inc.
Website
News25/Ratings12
News · 26 weeks85-77%
2025-10-262026-04-19
Mix3790d
- Insider14(38%)
- Other11(30%)
- SEC Filings8(22%)
- Earnings2(5%)
- Dividends1(3%)
- Leadership1(3%)
Latest news
25 items- PRAgilent Showcases Cancer Research Solutions at AACR 2026Agilent Technologies Inc. (NYSE:A) will present new technologies, scientific collaborations, and integrated workflows supporting cancer research and diagnostics at the American Association for Cancer Research (AACR) Annual Meeting on April 17–22, 2026, in San Diego, California. At the meeting, Agilent will highlight advances designed to connect discovery research, translational science, and companion diagnostics development, reflecting the growing demand for more integrated approaches across the cancer research continuum. Among the technologies featured is the BioTek Cytation 9 cell imaging multimode reader, the newest addition to the Cytation series of cell imaging and multimode micropla
- SECAmendment: Agilent Technologies Inc. filed SEC Form 8-K: Changes in Control of Registrant, Leadership Update, Financial Statements and Exhibits8-K/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
- SECAgilent Technologies Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
- INSIDERSEC Form 4 filed by Henson Meghan4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
- PRAgilent Announces the BioTek Cytation 9 Cell Imaging Multimode ReaderAgilent Technologies, Inc. (NYSE:A) today announced the launch of the BioTek Cytation 9 cell imaging multimode reader, the newest addition to the Cytation portfolio combining multimode microplate reading and high-content cell imaging in a single platform. Building on a decade of Cytation innovation and shaped by continuous customer feedback, the BioTek Cytation 9 helps laboratories move from samples to insights faster, supporting workflows from basic research through high‑content screening. Designed for researchers running both cell-based and biochemical assays, Cytation 9 brings expanded imaging capabilities along with advanced hybrid microplate detection technologies. Key features inc
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Agilent Technologies Inc.SCHEDULE 13G/A - AGILENT TECHNOLOGIES, INC. (0001090872) (Subject)
- PRAgilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) CarcinomaTest enables identification of patients whose tumors express PD-L1 for potential treatment with KEYTRUDA® (pembrolizumab)1, 2 Agilent Technologies Inc. (NYSE:A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to aid in identifying patients with esophageal or gastroesophageal junction (GEJ) carcinoma who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy. PD-L1 IHC 22C3 pharmDx, Code SK006, is the only FDA-approved companion diagnostic indicated to identify patients with esophageal or GEJ carcinoma whose tumors express PD-L1 (Combined Positive Score
- INSIDERSEC Form 4 filed by Rataj Sue H.4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
- INSIDERSEC Form 4 filed by Brawley Otis W4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
- INSIDERSEC Form 4 filed by Scangos George A4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
- INSIDERSEC Form 4 filed by Soriot Pascal4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
- INSIDERSEC Form 4 filed by Wilson Dow R4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
- INSIDERSEC Form 4 filed by Podolsky Daniel K4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
- INSIDERSEC Form 4 filed by Koh Boon Hwee4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
- INSIDERSEC Form 4 filed by Dolsten Mikael4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
- INSIDERSEC Form 4 filed by Brown Judy L4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
- INSIDERSEC Form 4 filed by Agilent Technologies Inc.4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
- SECAgilent Technologies Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
- PRAgilent Showcases Advances in Precision Oncology and Digital Pathology at USCAP 2026Expanded PD‑L1 indication and end‑to‑end digital pathology workflows support modern pathology practice Agilent Technologies Inc. (NYSE:A) today announced it will feature its latest advances in precision oncology and digital pathology workflows at the 2026 United States and Canadian Academy of Pathology (USCAP) Annual Meeting, taking place March 21-26 in San Antonio, Texas. Agilent will highlight expanded biomarker testing capabilities, continued progress in digital pathology adoption, and the evolving role of the Dako Omnis family of instruments as a foundation for scalable, automation‑ready pathology laboratories. At USCAP 2026, Agilent will feature its continued expansion in oncology
- PRAgilent Launches Agilent Advanced Therapeutics, Unifying CDMO Capabilities Across Canada and United StatesAgilent Technologies Inc. (NYSE:A) today announced the launch of Agilent Advanced Therapeutics, a unified Contract Development and Manufacturing Organization (CDMO) solution integrating the company's expanding capabilities across Canada and the United States. Agilent Advanced Therapeutics brings together the strengths of BIOVECTRA in Canada and Nucleic Acid Solutions in Colorado to deliver a full suite of premium, scalable and customizable manufacturing solutions. Agilent Advanced Therapeutics' CDMO portfolio includes oligonucleotides, microbial fermentation, complex and synthetic chemistry, bioreagents, highly potent APIs, and cell line development. The integrated platform provides cus
- PRExcellere Partners and GHO Capital Sell Biocare Medical to Agilent TechnologiesAgilent to acquire Biocare in an all-cash transaction valued at $950 millionTransaction follows significant period of growth under Excellere Partners and GHO Capital stewardship, with annual double-digit revenue and profit growth since 2021 Denver, CO and London, UK, 9 March 2026: Excellere Partners ("Excellere"), a Denver-based private equity firm specializing in partnering with entrepreneurs and management teams, GHO Capital Partners LLP ("GHO"), a specialist investor in global healthcare, and Biocare Medical ("Biocare"), a global leader of immunohistochemistry (IHC), in situ hybridization (ISH) and fluorescence in situ hybridization (FISH) solutions, today announce that Biocare has enter
- PRAgilent to Acquire Biocare Medical, a Global Leader in Clinical and Research Pathology SolutionsExpands Agilent's pathology portfolio through addition of highly complementary antibody, reagent and instrument business with annual double-digit revenue and profit growth since 2021 Expected to be accretive to Agilent's top-line growth rate, margin profile and non-instrument revenue mix in Year 1 Agilent Technologies Inc. (NYSE:A) today announced it has entered into a definitive agreement to acquire Biocare Medical, a global leader in clinical pathology, from an investor group led by Excellere Partners and GHO Capital Partners LLP, in an all-cash transaction valued at $950 million. Biocare is a high-growth global pathology antibody leader, serving customers with a complementary portf
- SECAgilent Technologies Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
- SECSEC Form 10-Q filed by Agilent Technologies Inc.10-Q - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
- INSIDERSenior Vice President Riemann Angelica covered exercise/tax liability with 89 shares, decreasing direct ownership by 0.33% to 26,535 units (SEC Form 4)4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)